Biopsy

Cancer Diagnostics Global Market Report 2022: Lifestyle Shifts Increasing Prevalence of Cancer and Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022

The global cancer diagnostics market size is expected to reach USD 293.5 billion by 2030., expanding at a CAGR of 6.89% from 2022 to 2030.

Key Points: 
  • The global cancer diagnostics market size is expected to reach USD 293.5 billion by 2030., expanding at a CAGR of 6.89% from 2022 to 2030.
  • Continual introduction of innovative products, coupled with increasing need for early diagnosis of various diseases, is a prime factor driving the market.
  • The demand for cancer diagnosis tools is significantly increasing worldwide due to technological advancements in the field of diagnosis.
  • Thus, rising prevalence of cancer globally is anticipated to create significantly boost the demand for diagnostic products during the forecast period.

Global Needles Market Report 2022: Expanding Injectables Market Presents Lucrative Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 30, 2022

The Bevel Needles accounted for the largest market share in the Conventional Needle Market, during the forecast period.

Key Points: 
  • The Bevel Needles accounted for the largest market share in the Conventional Needle Market, during the forecast period.
  • The Conventional Needle Market is segmented into Bevel Needles, Blunt Fill Needles, Vented Needles, and Filter Needles.
  • Based on type, the safety Needles market is segmented into Active Needles and Passive Needles.
  • The global needles market is divided into four regions: North America, Asia-Pacific, Europe, and the Rest of the World.

Theralase Releases Q322 Interim Financial Statements

Retrieved on: 
Tuesday, November 29, 2022

Theralase plans to commence GLP toxicology studies in animals in 4Q2022.

Key Points: 
  • Theralase plans to commence GLP toxicology studies in animals in 4Q2022.
  • Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations and a COVID-19 vaccine.
  • All forward-looking statements are made as of the date hereof and are subject to change.
  • Except as required by law, the Company assumes no obligation to update such statements.

High Deductible Leads Women to Skip Testing after Abnormal Mammogram

Retrieved on: 
Tuesday, November 29, 2022

But while HDHPs offer some advantages, the high out-of-pocket deductible costin excess of $1,400 for individuals and $2,800 for familiesmay prevent people from seeking necessary care.

Key Points: 
  • But while HDHPs offer some advantages, the high out-of-pocket deductible costin excess of $1,400 for individuals and $2,800 for familiesmay prevent people from seeking necessary care.
  • However, there is a lack of research into patient adherence to the recommended follow-up imaging when there is a deductible.
  • Of 707 respondents, 129 (18.3%) said they would skip the screening mammography exam, 465 (65.8%) would not skip mammography, and 113 (16.0%) were undecided.
  • "The results show that a deductible payment for follow-up breast imaging after an abnormal finding on screening mammography discourages 21% of women from returning for additional evaluation and appears to lead 18% of women to skip the initial free screening altogether," Dr. Ngo said.

Outlook on the Biopsy Global Market to 2027 - Industry Trends, Growth, Impact of Inflation and Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022

Long-term trends in cancer burden and rates reflect patterns in cancer-risk behaviors and changes in medical practice, such as the adoption of cancer screening tests.

Key Points: 
  • Long-term trends in cancer burden and rates reflect patterns in cancer-risk behaviors and changes in medical practice, such as the adoption of cancer screening tests.
  • However, rising population aging and the cumulative impact of risk factor exposure mean that cancer prevention faces many new obstacles.
  • Trends in China Biopsy Industry Prevailing Currently:
    China is transitioning to developed-country cancer profiles, including high breast cancer rates, prostate cancer, lung cancer, liver cancer, thyroid cancer, colon and rectum cancer, kidney cancer, leukemia cancer, pancreatic cancer, and bladder cancer.
  • As a result, China Biopsy Market Size is expected to expand at a CAGR of 6.25% during 2021-2027.

Europe Biopsy Devices Market Analysis Report 2022: Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022

The "Europe Biopsy Devices Market, Size, Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Biopsy Devices Market, Size, Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Biopsy guiding systems, needle-based biopsy guns, biopsy needles, and biopsy forceps are the most often used biopsy instruments.
  • Increased investments in R&D activities are driving the Europe Biopsy Devices Market.
  • According to our analysis, the Europe Biopsy Devices Market was negatively impacted from the end of 2019 to the beginning of 2020.

Aquyre Biosciences Reaches Major Procedure Milestone During Lung Awareness Month

Retrieved on: 
Wednesday, November 16, 2022

Aquyre Biosciences recognizes Lung Cancer Awareness Month by reaching a milestone of over 400 lung biopsy procedures completed using the CelTivity microscopic system.

Key Points: 
  • Aquyre Biosciences recognizes Lung Cancer Awareness Month by reaching a milestone of over 400 lung biopsy procedures completed using the CelTivity microscopic system.
  • View the full release here: https://www.businesswire.com/news/home/20221115006522/en/
    Image shows lung cancer detected using CelTivity microscope and virtual stain options.
  • We are thrilled to have quickly reached such a milestone and accelerate the accurate diagnosis of patients, said Aquyre Biosciences CEO Bertrand Le Conte De Poly.
  • Aquyre Biosciences, Inc is the creator of CelTivity, the industry leader in two-minute lung biopsy adequacy assessment.

Early detection and robotic technology helped save Texas Health patient April Boudreau's life

Retrieved on: 
Thursday, November 24, 2022

Early detection and robotic technology helped save April Boudreau's life.

Key Points: 
  • Early detection and robotic technology helped save April Boudreau's life.
  • So, when her yearly CT scan revealed a worrisome nodule on her right lung in January, doctors assumed it was cancer.
  • In select cases like Boudreau's, Texas Health Fort Worth's multidisciplinary thoracic oncology program can provide patients a holistic approach to lung cancer care by combining robotic-assisted bronchoscopy technology with robotic minimally invasive surgery.
  • Texas Health Resources is a faith-based, nonprofit health system that cares for more patients in North Texas than any other provider.

The Foundation for Sarcoidosis Research (FSR) to provide $50,000 in Sarcoidosis Research Funding Exploring Environmental Causes of sarcoidosis and for Identifying Neurosarc Biomarkers

Retrieved on: 
Thursday, November 24, 2022

CHICAGO, Nov. 23, 2022 /PRNewswire/ -- The Foundation for Sarcoidosis Research (FSR) is pleased to announce the funding for two new pilot projects in sarcoidosis.

Key Points: 
  • CHICAGO, Nov. 23, 2022 /PRNewswire/ -- The Foundation for Sarcoidosis Research (FSR) is pleased to announce the funding for two new pilot projects in sarcoidosis.
  • These research projects show great promise in advancing the understanding, diagnosis, and management of sarcoidosis.
  • FSR is dedicated to accelerating sarcoidosis research through fellowships, small grants, large grants, and disease specific grants to advance sarcoidosis research and advance care for those living with sarcoidosis.
  • The Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and to improving care for sarcoidosis patients through research, education, and support.

Body Vision Medical Announces Market Entry and First Customer in India

Retrieved on: 
Thursday, November 17, 2022

CAMPBELL, Calif., Nov. 17, 2022 /PRNewswire/ -- Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced today they have signed an exclusive distribution agreement with SCHILLER Healthcare India Pvt. Ltd., and that Yashoda Hospitals in Hyderabad plans to acquire a LungVision™ System, which, upon installation, will be the first in India.

Key Points: 
  • Body Vision Medical's LungVision System uses artificial intelligence (AI) to transform X-ray images from any C-arm into real-time, intraoperative CT scans.
  • Body Vision Medical's strategic partnership with SCHILLER Healthcare India will accelerate Body Vision's penetration of the Indian market.
  • "We are pleased to collaborate with Body Vision Medical to distribute and support their products in India," said Vikram Sanghvi, CEO and MD of SCHILLER Healthcare India Pvt.
  • https://doi.org/10.1136/bmj.l408
    Body Vision Medical specializes in AI-driven, intraoperative imaging with the aim of saving lives through the democratization of innovative medical technology.